Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent

PHASE2UnknownINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

November 30, 2020

Conditions
Coronary Artery DiseaseMyocardial Ischemia
Interventions
DEVICE

AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold

Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.

Trial Locations (5)

Unknown

Azienda Policlinico-Vittorio Emanuele, Universita di Catania, Catania

Ospedale San Raffaele, Milan

A. O. U. Federico II˚ Policlinico, Napoli

Policlinico Universitario, Padua

A. O. Ordine Mauriziano Umberto I, Torino

Sponsors
All Listed Sponsors
lead

Amaranth Medical Inc.

INDUSTRY